1. Search Result
Search Result
Results for "

transforming growth factor-β2-treated human anterior capsules

" in MedChemExpress (MCE) Product Catalog:

9717

Inhibitors & Agonists

60

Screening Libraries

16

Fluorescent Dye

45

Biochemical Assay Reagents

496

Peptides

31

MCE Kits

322

Inhibitory Antibodies

347

Natural
Products

7176

Recombinant Proteins

78

Isotope-Labeled Compounds

540

Antibodies

6

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0089A

    growth Hormone Releasing factor human TFA; Somatorelin (1-44) amide (human) (TFA)

    GHSR Endocrinology
    Human growth hormone-releasing factor TFA (Growth Hormone Releasing Factor human TFA) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary .
    <em>Human</em> <em>growth</em> hormone-releasing <em>factor</em> TFA
  • HY-P0118B
    Disitertide diammonium
    10+ Cited Publications

    P144 diammonium

    TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer [2] .
    Disitertide diammonium
  • HY-P0089

    growth Hormone Releasing factor human; Somatorelin (1-44) amide (human)

    GHSR Endocrinology
    Human growth hormone-releasing factor (Growth Hormone Releasing Factor human) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary .
    <em>Human</em> <em>growth</em> hormone-releasing <em>factor</em>
  • HY-P0118

    P144

    TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer [2] .
    Disitertide
  • HY-P0118A

    P144 TFA

    TGF-beta/Smad PI3K Apoptosis Cancer
    Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer [2] .
    Disitertide TFA
  • HY-B1888B

    Bromfenac monosodium salt sesquihydrate

    COX Infection Inflammation/Immunology
    Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium hydrate can be used in ocular inflammation research .
    Bromfenac sodium hydrate
  • HY-B1888A

    COX Infection Inflammation/Immunology
    Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium can be used in ocular inflammation research .
    Bromfenac sodium
  • HY-B1888

    COX Infection Inflammation/Immunology
    Bromfenac is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac can be used in ocular inflammation research .
    Bromfenac
  • HY-E70008

    Sirtuin Inflammation/Immunology
    Lumbokinase capsules attenuates myocardial ischemia-reperfusion (I-R) injury through the activation of Sirt1 signaling, and thus enhances autophagic flux and reduces I-R-induced oxidative damage, inflammation and apoptosis .
    Lumbokinase <em>capsules</em>
  • HY-P4012

    Vasopressin Receptor Endocrinology
    [Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture [2].
    [Asu1,6-Arg8]Vasopressin
  • HY-P3169

    CRFR Inflammation/Immunology
    α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo [2].
    a-Helical Corticotropin Releasing <em>Factor</em> (9-41)
  • HY-108905

    human IGF-I; FK 780

    IGF-1R Metabolic Disease
    Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
    Mecasermin
  • HY-P1085

    EGFR Cancer
    Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .
    Epidermal <em>Growth</em> <em>Factor</em> Receptor Peptide (985-996)
  • HY-P1777

    Insulin-like growth factor I (24-41)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development [2] .
    IGF-I (24-41)
  • HY-P99288

    Pamrevlumab; Anti-human CTGF Recombinant Antibody

    Apoptosis Cancer
    FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) [2].
    FG-3019
  • HY-P3601

    FGF basic (1-24)

    Bacterial HBV Infection Inflammation/Immunology
    Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research .
    Brain Derived Basic Fibroblast <em>Growth</em> <em>Factor</em> (1-24)
  • HY-145110

    IGF-1R Cancer
    IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis .
    IGF-1R inhibitor-<em>2</em>
  • HY-P1777A

    Insulin-like growth factor I (24-41) (TFA)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development [2] .
    IGF-I (24-41) (TFA)
  • HY-157420

    VEGFR Cardiovascular Disease
    VEGFR-2-IN-38 (compound 3) is a potential vascular endothelial growth factor receptor-2 inhibitor .
    VEGFR-<em>2</em>-IN-38
  • HY-N11004

    Others Neurological Disease
    Erinacine C is a potent stimulator. Erinacine C can be used for nerve-growth factor synthesis .
    Erinacine C
  • HY-142967

    TGF-β Receptor Cancer
    TGFβ-IN-1 is an antitumor growth and metastasis agent through inhibiting the transforming growth factor‑β signaling pathway.
    TGFβ-IN-1
  • HY-13012
    RepSox
    15+ Cited Publications

    E-616452; SJN 2511

    Organoid TGF-β Receptor Metabolic Disease
    RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes [2].
    RepSox
  • HY-147615

    c-Fms Cancer
    CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) .
    CSF1R-IN-12
  • HY-147616

    c-Fms Cancer
    CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .
    CSF1R-IN-13
  • HY-P3685

    CRFR Endocrinology
    [Met(O)21] Corticotropin Releasing Factor, ovine is a corticotropin releasing factor isolated from ovine hypothalamic extracts. Corticotropin releasing factor (CRF) is a hypothalamic hormone, which stimulates the secretion of adrenocorticotrophic hormone (ACTH) .
    [Met(O)21] Corticotropin Releasing <em>Factor</em>, ovine
  • HY-157049

    Others Others
    Caprylocaproyl Macrogolglycerides is a lipoidic excipient/vehicle in an oral capsule formulation. Caprylocaproyl Macrogolglycerides can enhance the absorption of small molecule compounds .
    Caprylocaproyl Macrogolglycerides
  • HY-12043
    SB 525334
    5+ Cited Publications

    TGF-β Receptor Cancer
    SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.
    SB 525334
  • HY-132259

    ABT-414

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .
    Depatuxizumab mafodotin
  • HY-13783

    TGF-β Receptor Cancer
    BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC50 of 34 nM.
    BIBF0775
  • HY-147393

    Others Cardiovascular Disease
    Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC50 of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties .
    <em>Factor</em> VII-IN-1
  • HY-N10577

    TGF-beta/Smad Cancer
    Chlorfortunone A is a novel sesquiterpenoid dimers, can be isolated from the roots of Chloranthus fortunei. Chlorfortunone A inhibits transforming growth factor (TGF)-β activity .
    Chlorfortunone A
  • HY-118203

    FGFR PDGFR Insulin Receptor Cancer
    SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer [2] .
    SU4984
  • HY-138298
    Trastuzumab deruxtecan (solution)
    1 Publications Verification

    DS-8201 (solution); DS-8201a (solution)

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer [2].
    Trastuzumab deruxtecan (solution)
  • HY-N12170

    Others Neurological Disease
    Kissoone C (compound 3) is a three-membered ring sesquiterpene isolated from valerian root. Kissoone C can enhance the activity of nerve growth factor (NGF)-mediated neurite outgrowth in PC12D cells .
    Kissoone C
  • HY-13894
    Tyrphostin AG1296
    1 Publications Verification

    AG1296

    PDGFR c-Kit FLT3 Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range [2] .
    Tyrphostin AG1296
  • HY-P99217

    AMG 102

    c-Met/HGFR Cancer
    Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research [2].
    Rilotumumab
  • HY-78349
    A 77-01
    1 Publications Verification

    TGF-β Receptor Cancer
    A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM .
    A 77-01
  • HY-P1304A

    Neuropeptide Y Receptor Neurological Disease
    CART(55-102)(human) TFA is a human satiety factor with potent appetite-suppressing activity. CART(55-102)(human) TFA is closely associated with leptin and neuropeptide Y [2].
    CART(55-102)(<em>human</em>) TFA
  • HY-112331
    SJ000291942
    3 Publications Verification

    TGF-β Receptor Cancer
    SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway. BMPs are members of the transforming growth factor beta (TGFβ) family of secreted signaling molecules.
    SJ000291942
  • HY-147617

    c-Fms Cancer
    CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) .
    CSF1R-IN-14
  • HY-B1350A
    Fusidic acid sodium salt
    2 Publications Verification

    Sodium fusidate; SQ-16360

    Bacterial Antibiotic Infection Cancer
    Fusidic acid sodium salt (Sodium fusidate), a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid sodium salt has no corticosteroid effects. Fusidic acid sodium salt inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome [2].
    Fusidic acid sodium salt
  • HY-B1350
    Fusidic acid
    2 Publications Verification

    Fusidate; SQ-16603

    Bacterial Antibiotic Infection Cancer
    Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome [2].
    Fusidic acid
  • HY-110171
    iMDK
    1 Publications Verification

    PI3K Cancer
    iMDK is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice .
    iMDK
  • HY-138281

    Complement System Inflammation/Immunology
    Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .
    Complement <em>factor</em> D-IN-<em>2</em>
  • HY-P99720

    ACE-536; luspatercept–aamt

    TGF-beta/Smad Metabolic Disease
    Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
    Luspatercept
  • HY-101837

    Others Inflammation/Immunology
    CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .
    CGP 53716
  • HY-110171A
    iMDK quarterhydrate
    1 Publications Verification

    PI3K Cancer
    iMDK quarterhydrate is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice .
    iMDK quarterhydrate
  • HY-10262
    BMS-536924
    3 Publications Verification

    IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity [2].
    BMS-536924
  • HY-B1350R

    Fusidate (Standard); SQ-16603 (Standard)

    Antibiotic Bacterial Cancer
    Fusidic acid (Standard) is the analytical standard of Fusidic acid. This product is intended for research and analytical applications. Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome [2].
    Fusidic acid (Standard)
  • HY-P1773A

    Insulin-like growth factor I (30-41) (TFA)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
    IGF-I (30-41) (TFA)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: